The estimated Net Worth of Harold E Selick is at least 211 千$ dollars as of 7 March 2024. Harold Selick owns over 6,490 units of Molecular Templates Inc stock worth over 38,355$ and over the last 15 years he sold MTEM stock worth over 0$. In addition, he makes 172,552$ as Chairman of the Board at Molecular Templates Inc.
Sign up
Harold Selick MTEM stock SEC Form 4 insiders trading
Harold has made over 5 trades of the Molecular Templates Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 6,490 units of MTEM stock worth 12,266$ on 7 March 2024.
The largest trade he's ever made was buying 12,000 units of Molecular Templates Inc stock on 12 March 2020 worth over 80,400$. On average, Harold trades about 872 units every 87 days since 2009. As of 7 March 2024 he still owns at least 27,996 units of Molecular Templates Inc stock.
You can see the complete history of Harold Selick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Harold Selick biography
Dr. Harold E. Selick Ph.D. serves as Chairman of the Board of the Company. He is chairman of the Company’s Board, and has served as a director of the Company since August 2017, effective as of the Merger, and served as a Pre-Merger director of Threshold since June 2002. He is currently the Vice Chancellor of Business Development, Innovation and Partnerships at the University of California, San Francisco, a position that he has held since April 2017. Previously, Dr. Selick served as Pre-Merger Threshold’s Chief Executive Officer from June 2002 until March 2017. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation and its wholly-owned subsidiary, Camitro UK, Ltd, biotechnology companies. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL) he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was initially developed and commercialized by Roche for the prevention of kidney transplant rejection and more recently developed by Biogen and AbbVie and approved as Zinbryta for treatment of adults with relapsing forms of multiple sclerosis. Dr. Selick received his B.A. in Biophysics and Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco. Our Board has concluded that Dr. Selick should serve as a director of the Company based on Dr. Selick’s extensive experience and industry knowledge.
What is the salary of Harold Selick?
As the Chairman of the Board of Molecular Templates Inc, the total compensation of Harold Selick at Molecular Templates Inc is 172,552$. There are 9 executives at Molecular Templates Inc getting paid more, with Eric Poma having the highest compensation of 1,733,740$.
How old is Harold Selick?
Harold Selick is 65, he's been the Chairman of the Board of Molecular Templates Inc since 2017. There are 1 older and 18 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.
What's Harold Selick's mailing address?
Harold's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160.
Insiders trading at Molecular Templates Inc
Over the last 7 years, insiders at Molecular Templates Inc have traded over 22,993,582$ worth of Molecular Templates Inc stock and bought 14,744,530 units worth 82,519,716$ . The most active insiders traders include Target N Vbb Biotech Ag Bio...、David Hirsch、Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of 532,718$. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth 587,500$.
What does Molecular Templates Inc do?
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
What does Molecular Templates Inc's logo look like?
Complete history of Harold Selick stock trades at Catalyst Biosciences Inc、PDL Biopharma Inc、Protagonist Therapeutics Inc、Molecular Templates Inc
Molecular Templates Inc executives and stock owners
Molecular Templates Inc executives and other stock owners filed with the SEC include:
-
Eric Poma,
Chief Executive Officer, Chief Scientific Officer, Director -
Roger Waltzman,
Chief Medical Officer -
Jason Kim,
President, Chief Operating Officer -
Adam Cutler,
Chief Financial Officer, Treasurer, Secretary -
Dr. Eric E. Poma,
CEO, Chief Scientific Officer & Director -
Dr. Roger J. Waltzman M.B.A., M.D.,
Chief Medical Officer -
Jason S Kim,
Pres & COO -
Dr. Roger J. Waltzman,
Chief Medical Officer -
Corazon Sanders,
Independent Director -
Harold Selick,
Chairman of the Board -
Kevin Lalande,
Independent Director -
David Hirsch,
Independent Director -
David Hoffmann,
Independent Director -
Scott Morenstein,
Independent Director -
Jonathan Lanfear,
Independent Director -
Michael Dowd,
Sr. VP of Project & Alliance Management -
Megan C. Filoon,
Gen. Counsel & Sec. -
Dr. Nenad Sarapa M.D., M.S.,
Sr. VP of Clinical Devel. -
Dr. Jen-Sing Liu Ph.D.,
Exec. VP of Manufacturing -
Dr. Erin Willert Ph.D.,
Exec. VP of R&D -
Dr. Jack Higgins Ph.D.,
Exec. VP of Operations & Head of Manufacturing -
Kurt Elster,
Exec. VP of Corp. Devel. -
Sean McLennan,
Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer -
Associates, L.L.C.Morenstei...,
-
Target N Vbb Biotech Ag Bio...,
-
Dave Hoffmann,
Director -
Capital Partners Iii, Llc L...,
-
Scott Dcdk Associates, L.L....,
-
Management Services, Llc Cu...,
-
Sean Mc Lennan,
See remarks -
Management Services, Llc Cu...,
-
Gabriela Gruia,
Director -
Maurizio Voi,
Chief Medical Officer